MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

5.39 -3.92

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.38

Max

5.68

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.97% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

240M

742M

Eelmine avamishind

9.31

Eelmine sulgemishind

5.39

Uudiste sentiment

By Acuity

17%

83%

18 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. jaan 2026, 23:29 UTC

Kuumad aktsiad

Stocks to Watch: Atossa Therapeutics, Union Pacific

16. jaan 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. jaan 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 21:48 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. jaan 2026, 21:41 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. jaan 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. jaan 2026, 20:44 UTC

Tulu

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. jaan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. jaan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. jaan 2026, 19:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16. jaan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16. jaan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16. jaan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16. jaan 2026, 16:32 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16. jaan 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

10.97% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  10.97%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

18 / 361 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat